Start-up
IGUANA BIOTECHNOLOGY GmbH
About IGUANA BIOTECHNOLOGY
Iguana Biotechnology GmbH (Iguana), an innovative BioTech start-up based in Munich, Germany, is pursuing as a lead candidate the development of a therapeutic vaccine against Helicobacter pylori, one of the most common infectious diseases worldwide.
Currently, around 50% of the world's population is affected by this infection. Early diagnosis and treatment of the infection can significantly reduce the risk of serious gastric diseases such as gastric ulcers, MALT lymphoma and gastric cancer. Due to increasing resistance to conventional antibiotic therapy, the development of effective therapeutic alternatives is essential. Iguana, with its innovative approach, meets the urgent need for such a vaccine and thus contributes to reducing the risk of gastric cancer.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
- Founding: 2021
- Focus : Manufacturer
- Industry : Biotechnology
